Alphamab Oncology Balance Sheet Health
Financial Health criteria checks 5/6
Alphamab Oncology has a total shareholder equity of CN¥1.7B and total debt of CN¥250.0M, which brings its debt-to-equity ratio to 15%. Its total assets and total liabilities are CN¥2.1B and CN¥465.0M respectively.
Key information
15.0%
Debt to equity ratio
CN¥250.00m
Debt
Interest coverage ratio | n/a |
Cash | CN¥1.41b |
Equity | CN¥1.67b |
Total liabilities | CN¥465.00m |
Total assets | CN¥2.14b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 3NK's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥266.8M).
Long Term Liabilities: 3NK's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥198.2M).
Debt to Equity History and Analysis
Debt Level: 3NK has more cash than its total debt.
Reducing Debt: 3NK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3NK has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 3NK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.